» Articles » PMID: 37784005

RNA Nanomedicine: Delivery Strategies and Applications

Overview
Journal AAPS J
Specialty Pharmacology
Date 2023 Oct 2
PMID 37784005
Authors
Affiliations
Soon will be listed here.
Abstract

Delivery of RNA using nanomaterials has emerged as a new modality to expand therapeutic applications in biomedical research. However, the delivery of RNA presents unique challenges due to its susceptibility to degradation and the requirement for efficient intracellular delivery. The integration of nanotechnologies with RNA delivery has addressed many of these challenges. In this review, we discuss different strategies employed in the design and development of nanomaterials for RNA delivery. We also highlight recent advances in the pharmaceutical applications of RNA delivered via nanomaterials. Various nanomaterials, such as lipids, polymers, peptides, nucleic acids, and inorganic nanomaterials, have been utilized for delivering functional RNAs, including messenger RNA (mRNA), small interfering RNA, single guide RNA, and microRNA. Furthermore, the utilization of nanomaterials has expanded the applications of functional RNA as active pharmaceutical ingredients. For instance, the delivery of antigen-encoding mRNA using nanomaterials enables the transient expression of vaccine antigens, leading to immunogenicity and prevention against infectious diseases. Additionally, nanomaterial-mediated RNA delivery has been investigated for engineering cells to express exogenous functional proteins. Nanomaterials have also been employed for co-delivering single guide RNA and mRNA to facilitate gene editing of genetic diseases. Apart from the progress made in RNA medicine, we discuss the current challenges and future directions in this field.

Citing Articles

Current views and trends of nanomaterials as vectors for gene delivery since the 21st century: a bibliometric analysis.

Xiao X, Yang S, Jiang G, He S Nanomedicine (Lond). 2025; 20(5):439-454.

PMID: 39878523 PMC: 11875476. DOI: 10.1080/17435889.2025.2457781.


Advances in RNA-Based Therapeutics: Challenges and Innovations in RNA Delivery Systems.

Liu Y, Ou Y, Hou L Curr Issues Mol Biol. 2025; 47(1).

PMID: 39852137 PMC: 11763986. DOI: 10.3390/cimb47010022.


Antimicrobial Peptides Against Arboviruses: Mechanisms, Challenges, and Future Directions.

Owliaee I, Khaledian M, Shojaeian A, Madanchi H, Yarani R, Boroujeni A Probiotics Antimicrob Proteins. 2025; .

PMID: 39776036 DOI: 10.1007/s12602-024-10430-0.


Hybrid RNA/DNA Concatemers and Self-Limited Complexes: Structure and Prospects for Therapeutic Applications.

Kanarskaya M, Novikova S, Lomzov A Molecules. 2025; 29(24.

PMID: 39769985 PMC: 11677838. DOI: 10.3390/molecules29245896.


Cell membrane-coated mRNA nanoparticles for enhanced delivery to dendritic cells and immunotherapy.

Li Q, Byun J, Kim D, Wu Y, Lee J, Oh Y Asian J Pharm Sci. 2024; 19(6):100968.

PMID: 39640052 PMC: 11617980. DOI: 10.1016/j.ajps.2024.100968.


References
1.
Barbier A, Jiang A, Zhang P, Wooster R, Anderson D . The clinical progress of mRNA vaccines and immunotherapies. Nat Biotechnol. 2022; 40(6):840-854. DOI: 10.1038/s41587-022-01294-2. View

2.
Esrick E, Lehmann L, Biffi A, Achebe M, Brendel C, Ciuculescu M . Post-Transcriptional Genetic Silencing of to Treat Sickle Cell Disease. N Engl J Med. 2020; 384(3):205-215. PMC: 7962145. DOI: 10.1056/NEJMoa2029392. View

3.
Wang C, Zhang Y, Dong Y . Lipid Nanoparticle-mRNA Formulations for Therapeutic Applications. Acc Chem Res. 2021; 54(23):4283-4293. PMC: 10068911. DOI: 10.1021/acs.accounts.1c00550. View

4.
Sabnis S, Kumarasinghe E, Salerno T, Mihai C, Ketova T, Senn J . A Novel Amino Lipid Series for mRNA Delivery: Improved Endosomal Escape and Sustained Pharmacology and Safety in Non-human Primates. Mol Ther. 2018; 26(6):1509-1519. PMC: 5986714. DOI: 10.1016/j.ymthe.2018.03.010. View

5.
Frangoul H, Ho T, Corbacioglu S . CRISPR-Cas9 Gene Editing for Sickle Cell Disease and β-Thalassemia. Reply. N Engl J Med. 2021; 384(23):e91. DOI: 10.1056/NEJMc2103481. View